NeurologyLive® Year in Review 2025: Spotlighting SAP Collaborations

The NeurologyLive^® staff was hard at work in 2025, covering clinical news and data readouts from across the United States and beyond, spanning multiple neurology subspecialties. Between major study publications and FDA decisions, and traveling to societal conference sessions to conduct expert interviews, the team spent the year bringing the latest updates and insights to the website’s front page.

Throughout the year, the team has worked closely with over 30 organizations as part of NeurologyLive's Strategic Alliance Partnership (SAP) program. The program is constantly building a community of advocacy groups, medical associations, and medical institutions to foster collaboration and exchange information among trusted peers, to benefit patients and their families. As part of this joint effort, NeurologyLive works with partners to exclusively share information with the ultimately goal to improve patient outcomes.

Here, we'll highlight some of the top collaborative interviews with SAPs on NeurologyLive this year.

1. Impact of COVID-19 Vaccination on Neurologic Manifestations of Long COVID: Igor Koralnik, MD

SAP: Northwestern Medicine

In the beginning of the year, in January 2025, NeurologyLive spoke with Igor Koralnik, MD, chief of neuroinfectious diseases and global neurology at Northwestern Medicine, who discussed how addressing the neurologic burden of Long COVID requires a multidisciplinary approach that prioritizes cognitive rehabilitation, mental health support, and symptom-specific management to improve quality of life. Koralnik also highlighted the need for further research to unravel the mechanisms driving neurologic symptoms in Long COVID and to identify effective interventions.

Click here to view more of our collaborations with Northwestern Medicine.

2. Updates on Guidance for Diagnosing Pediatric and Late-Onset Multiple Sclerosis: Andrew Solomon, MD

SAP: National MS Society

In March, 2025, NeurologyLive spoke with Andrew Solomon, MD, a neurologist at the University of Vermont (UVM) Medical Center, about the significant work of the MS Differential Diagnosis Consortium (MSDDC). In this interview, Solomon, who also serves as a professor of neurological sciences at the Larner College of Medicine at UVM, discussed the persistent challenges of MS misdiagnosis, the limitations of current biomarkers, and the necessity of a structured diagnostic approach that carefully evaluates alternative conditions.

Click here to view more of our collaborations with National MS Society.

3. Treatment Decisions and Personalization for Pediatric MOGAD: Kelsey Poisson, MD

SAP: Siegel Rare Neuroimmune Association

In March 2025, Kelsey Poisson, MD, a child neurologist and neuroimmunologist at Nationwide Children’s Hospital, spoke with NeurologyLive to discuss the treatment course for pediatric MOGAD. In the discussion, she emphasized the need for more research to determine which patients require maintenance therapy versus just acute treatment. Poisson, who also serves as an assistant professor at clinical pediatrics and neurology at The Ohio State University College of Medicine, highlighted the importance of individualized care, factoring the child’s preferences, age, and ability to tolerate treatments.

Click here to view more of our collaborations with Siegel Rare Neuroimmune Association.

4. Addressing Constipation, Sleep, and Fatigue in Parkinson Disease Care: Alexa Dessy, MD

SAP: Jefferson Health

In August 2025, Alexa Dessy, MD, clinical assistant professor in movement disorders at Jefferson Health, spoke with NeurologyLive to learn more about the importance of treating secondary symptoms of Parkinson disease. Dessy, who studied at NYU School of Medicine, discussed the importance of addressing nonmotor symptoms in PD–such as constipation, apathy, fatigue, and sleep issues–that can have as much impact on quality of life as motor fluctuations.

Click here to view more of our collaborations with Jefferson Health.

5. Clinical Experience and Considerations With ALS Medication Tofersen: Sandeep Rana, MD

SAP: Allegheny Health Network

In August 2025, Sandeep Rana, MD, a neurophysiologist at Allegheny Health Network, spoke with NeurologyLive about his recent experience with tofersen in treating patients with SOD1 ALS. In the interview, Rana provided his initial clinical perspectives, explaining how this treatment is designed to slow or halt disease progression, with biomarker evidence already suggesting favorable effects in many patients. Rana discussed the critical role of genetic testing in ensuring timely identification of eligible patients, particularly in community and non-urban settings where access to advanced therapies can be limited.

Click here to view more of our collaborations with Allegheny Health Network.

6. Enhancing Gene Therapy Safety for Duchenne Through New Recommendations: Barry Byrne, MD, PhD

SAP: Muscular Dystrophy Association

In September 2025, NeurologyLive spoke with Barry Byrne, MD, PhD, chief medical adviser at the Muscular Dystrophy Association, about some of the topline considerations clinicians should take away from the recently published consensus guidelines for safe and equitable use of gene therapy in DMD. Byrne outlined the standard protocols for monitoring adverse events related to gene therapies, highlighting the importance of weekly liver function testing and the potential role of adjunctive agents like rapamycin to mitigate risks and improve therapeutic efficacy.

Click here to view more of our collaborations with Muscular Dystrophy Association.

7. Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhD

SAP: Cleveland Clinic

In September 2025, NeurologyLive spoke with Paul Ford, PhD, the director of the Neuroethics Program at Cleveland Clinic, Ford discussed the role of ethics education and structured safeguards in clinical care and research, particularly when patients also serve as research participants. He highlighted the need for clinicians, researchers, patients, and families to build skills for navigating complex technologies and decisions, respectfully and collaboratively. Ford described how integrating ethics into multidisciplinary teams ensures informed, safe, and patient-centered decision-making.

Click here to view more of our collaborations with Cleveland Clinic.

8. The Changing Landscape of Epilepsy Care: Orrin Devinsky, MD

SAP: NYU Langone Health

In September 2025, NeurologyLive spoke with Orrin Devinsky, MD, director of NYU Langone’s Comprehensive Epilepsy Center, reflected on the way epilepsy care has grown over the years. He emphasized the promise of antisense oligonucleotides and gene replacement strategies in rare epilepsies. Devinsky also underscored the importance of tackling premature mortality, particularly sudden unexplained death in epilepsy, by increasing awareness among clinicians and patients and advancing safer pregnancy management for women with epilepsy.

Click here to view more of our collaborations with NYU Langone Health.

9. Understanding Key Clinical and Genetic Biomarkers in Huntington Disease Research: Sarah O'Shea, MD, MSc

SAP: Icahn School of Medicine at Mount Sinai

In October 2025, NeurologyLive spoke with Sarah O'Shea, MD, MSc, associate professor of neurology at the Icahn School of Medicine at Mount Sinai, who described the range of biomarkers used to understand and monitor Huntington disease, emphasizing clinical and genetic measures. She highlighted the Unified Huntington’s Disease Rating Scale and total functional capacity scale as standard clinical tools for assessing motor, cognitive, and functional decline. On the genetic side, O’Shea noted that the number of CAG repeats in the HTT gene and the presence of mutant HTT can serve as definitive indicators for diagnosis and therapeutic monitoring.

Click here to view more of our collaborations with Icahn School of Medicine at Mount Sinai.

10. Practical Pathways for Ruptured vs Unruptured Aneurysms: Guilherme Dabus, MD

SAP: Baptist Health

In October 2025, NeurologyLive spoke with Guilherme Dabus, MD, codirector of interventional neuroradiology at Baptist Health's Neuroscience Institute, to discuss the decision-making process for ruptured versus unruptured aneurysms, particularly as technology continues to evolve. Dabus provided clinical insights on how each case may differ, emphasizing that each individual should have treatment plans tailored to the aneurysm location, neck morphology, age/frailty, and the full endovascular armamentarium. He touched on several approaches: simple coiling, stent-assisted coiling, flow diversion, and intrasaccular flow disruptors.

Click here to view more of our collaborations with Baptist Health.